12:00 AM
Jun 03, 2013
 |  BC Week In Review  |  Company News  |  Deals

Bausch + Lomb, Valeant Pharmaceuticals deal

Valeant will acquire ophthalmic company Bausch + Lomb for $8.7 billion in cash. About $4.5 billion will go to an investor group led by Warburg Pincus and about $4.2 billion will repay debt. Valeant said the deal will be financed by a fully committed debt financing from Goldman Sachs, as well as the sale of $1.5-$2 billion in new equity. Bausch +...

Read the full 290 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >